CLOVES Syndrome clinical trials at UCSF
1 research study open to eligible people
CLOVES syndrome involves abnormal tissue growth due to specific gene mutations. UCSF is running trials to test targeted therapies for the syndrome. Researchers are examining a drug named RLY-2608, assessing its impact on people with these genetic changes.
Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
open to eligible people ages 2 years and up
This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, RLY-2608, in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose selection, Part 2 is a basket design with exploratory single-arm cohorts for various subpopulations of participants, and Part 3 is randomized, double-blinded study vs placebo.
San Francisco, California and other locations
Last updated: